Unknown Manufacturer
Maftivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Maftivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Ebola virus (EBOV) is one of several viruses within the Ebolavirus genus known to infect humans with an average case fatality rate of 43.92%. EBOV particles expose the GP glycoprotein on their surface, which comprises a trimer of GP and GP subunit heterodimers, with the subunits connected by a disulfide bond. GP plays an important role in both cell surface attachment/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1/Niemann-Pick C1 protein (NPC1). In this manner, GP is integral to the pathogenic cycle of EBOV. Maftivimab is a fully-humanized IgG1κ monoclonal antibody (mAb) directed against the EBOV GP glycoprotein, which binds between GP1 and GP2 protomers at the base of the GP protein with a binding affinity (K) of between 2.97 and 3.34 nM. Maftivimab exhibits strong neutralization of chimeric lentiviral particles expressing EBOV GP with a half-maximal inhibitory concentration (IC) value or 0.17 nM, but lacks the ability to induce FcγRIIIa signalling in effector cells.. Combined with Odesivimab and Atoltivimab, Maftivimab works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells.
Maftivimab is indicated in combination with Odesivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. This combination has not been established as efficacious for any other species within either the Ebolavirus or Marburgvirus genera; special care should be taken to evaluate the susceptibility of circulating Zaire ebolavirus strains before beginning treatment, and the possible emergence of resistance should be monitored.
1 associated conditions
